Amedisys

35th Annual J.P. Morgan Healthcare Conference
January 11, 2017

Forward-looking Statements

This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events.

Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031.

We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law.

www.amedisys.com

NASDAQ: AMED

We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business and clinical operations and control processes, and SEC filings.

We intend to use our website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information.

Highlights and Summary Financial Results (Adjusted) – 3Q 2016 (1)

Amedisys Highlights

Amedisys Consolidated
- Revenue Growth: +11%
- EBITDA: $26M
- EBITDA Margin: 7.1%
- EPS: $0.36

Balance Sheet and Cash Flow
- Net debt: $88M
- Leverage ratio: 0.8x (net)
- CFFO bef. WC change (2) : $35M
- Free cash flow (2) : $4M

Home Health

Same Store Admissions:
- Medicare FFS: +1%
- Total Episodic: +3%
- Non-episodic: (7%)

Other Statistics:
- Medicare recert rate (3): 35%
- Cost per visit: +5%

Hospice

Same Store Volume:
- Admissions: +16%
- ADC: +14%

Other Statistics:
- Cost per day: 0%

Personal Care

Same Store Metrics:
- Billable hours/quarter: +8%
- Clients served: +11%

Adjusted Financial Results

$ in Millions, except EPS	3Q15	3Q16
Home Health	253.4	268.9
Hospice	73.0	82.0
Personal Care	-	10.7
Total Revenue	**$ 326.4**	**$ 361.6**
Gross Margin %	*42.8%*	*41.3%*
Adjusted EBITDA	**26.4**	**25.6**
	8.1%	*7.1%*
Adjusted EPS	**$0.34**	**$0.36**
Free cash flow (2)	29.4	3.9

1. *The financial results for the three-month periods ended September 30, 2015 and September 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.*
2. *CFFO before working capital change defined as cash flow from operations before working capital changes. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.*
3. *Recert Rate excluding Infinity impact and HCHB disruption: 37%*

Home Health and Hospice Segment (Adjusted) – 3Q 2016 (1)

HOME HEALTH $ in Millions	3Q15	3Q16
Medicare	190.2	203.9
Non-Medicare	63.2	65.0
Home Health Revenue	**$253.4**	**$268.9**
Gross Margin %	*40.8%*	*39.6%*
Segment EBITDA (2)	**34.6**	**31.9**
	13.7%	*11.9%*
Operating Statistics		
Medicare admit growth - same store	4%	1%
Medicare recertification rate (3)	38%	35%
Medicare admits	44,434	47,625
Medicare recertifications	25,420	25,522
Non-Medicare admit growth - same store	21%	-1%
Non-Medicare admits	24,792	24,335
Cost per visit	$87.54	$91.58

HOSPICE $ in Millions	3Q15	3Q16
Medicare	68.6	77.0
Non-Medicare	4.4	5.0
Hospice Revenue	**$73.0**	**$82.0**
Gross Margin %	*49.6%*	*48.9%*
Segment EBITDA (2)	**19.7**	**21.3**
	26.9%	*26.0%*
Operating Statistics		
Admit growth - same store	26%	16%
ADC growth - same store	17%	14%
Admits	4,962	5,751
ADC	5,346	6,087
Revenue per day	$148.47	$146.49
Cost per day	$74.82	$74.77

Home Health Highlights

- Medicare same store growth positive but below plan (+1%); revenue mix holding steady (76% Medicare FFS)
- Non-Medicare per visit admissions declined 7% during 3Q16 compared to prior year
- CPV increase driven by planned salary increases, HCHB disruption and health insurance expenses (75% of y/y increase)

Hospice Highlights

- Sixth straight quarter of double digit same store admissions growth; 12% y/y revenue increase
- Gross revenue per day down 1% y/y; gross margin contracted 70 basis points
- Cost per day flat

1. *The financial results for the three-month periods ended September 30, 2015 and September 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.*
2. *Segment EBITDA does not include any corporate G&A expenses*
3. *Recert Rate excluding Infinity impact and HCHB disruption: 37%*

General & Administrative Expenses – Adjusted [1,2]

$ in Millions, except EPS	3Q15	4Q15	1Q16	2Q16	3Q16
Home Health Segment	65.7	66.0	65.5	67.0	66.4
Acquisitions			4.9	4.3	4.3
Home Health Segment - Total	**65.7**	**66.0**	**70.4**	**71.3**	**70.7**
% of Home Health Revenue	*25.9%*	*25.1%*	*25.8%*	*25.9%*	*26.3%*
Hospice Segment	16.1	17.0	16.9	17.3	17.4
% of Hospice Revenue	*22.0%*	*22.4%*	*23.1%*	*22.6%*	*21.2%*
Personal Care Segment			0.4	2.3	2.2
% of Personal Care Revenue			*12.7%*	*24.5%*	*20.6%*
Corporate Expenses	26.7	29.5	28.6	27.5	26.8
Acq. Corporate Exp. + HCHB Fees	1.7	1.4	3.3	3.7	2.2
Total Corporate	**28.4**	**30.9**	**31.9**	**31.2**	**29.0**
% of Total Revenue	*8.7%*	*9.1%*	*9.1%*	*8.6%*	*8.0%*
Total	**110.2**	**113.9**	**119.6**	**122.1**	**119.3**
% of Total Revenue	***33.8%***	***33.6%***	***34.3%***	***33.8%***	***33.0%***

$ in Millions, except EPS	3Q15	4Q15	1Q16	2Q16	3Q16
Corporate Expense Detail (excl. Acquisitions and HCHB Fees)					
Salary and Benefits	15.8	15.8	15.3	15.9	15.8
Other	10.9	13.7	13.3	11.6	11.0
Subtotal	**26.7**	**29.5**	**28.6**	**27.5**	**26.8**



Highlights

- Year over year total G&A as a percentage of revenue decreased of 80 basis points despite inclusion of roughly $7M related to acquisitions; declined 130 bps since high point in 1Q16
    - Home health segment G&A: 40 bps y/y increase as % of revenue; mainly driven by health insurance increases and HCHB fees being allocated to the segment as implementation progresses
    - Hospice segment G&A: 80 bps decrease y/y as % of revenue
    - Corporate G&A: 70 bps decrease y/y and 110 bps since 1Q16 as % of total revenue

1. *The financial results for the three-month periods ended September 30, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.*
2. *Adjusted G&A expenses do not include bad debt expense or depreciation and amortization.*

Amedisys Strategy: Four Areas of Focus Updated 3Q 2016

Current:
- Quality of Patient care score: 4.03 for April 2017 preview
- 75% of centers at 4.0+ STARs in new preview data
- Patient Survey score: 3.76

Future Goals:
- All HH care centers at 4.0+ STARs at end of 2017
- Top of Hospice quality measures

Current:
- September full-time employee voluntary turnover was 18.0% down from 18.7%; total turnover of 22.8% down from 23.7%
- Productivity tool build and being piloted

Future Goals:
- Overall turnover target of 22% by year end 2016
- 10% productivity improvement by year end 2017

Current:
- All centers went live on HCHB Oct. 31 2016
- Over 90% of savings initiatives currently underway
- HCHB 2.0 – platform optimization training for the field

Future Goal:
- Realize HCHB enabled $46M in annualized improvement

Current:
- HH: 3Q16 same store Medicare admissions growth +1%, episodic +3%, non-episodic (7%)
- HH: Medicare mix: 76% of revenue
- HOSP: 3Q16 same store admissions growth 16%
- Inorganic: TTM deployed $100M in capital on M&A

Future Goal:
- HH targeting 5-6% annual organic growth through redesign and productivity of sales force

How We're Tracking

Status	Category	Update
	STARS	Good progress on QPC Stars with April 17 preview score of 4.03
	VBP	Value Based Purchasing (VBP) has seen strong performance in internal reporting, and we expect to be a net receiver of funds in 2018
	Protocols / Clinical Standardization	Create innovative industry-leading, clinical programs and define, develop and implement standardized care protocols at point of care
	Turnover	Overall turnover dropped to 22.8% with full time turnover down to 18%
	Productivity	Proprietary productivity and staffing tool being piloted – tool will optimize clinical capacity while allowing clinicians to work "at the top of their license"
	HCHB Rollout & Disruption	Last 32 care centers rolled-out HCHB Oct. 31st. Completed installation in 15 month. Choppiness is deeper, than originally predicated, but will wind down in 1Q'17
	HCHB 2.0	Re-training the field to become system "super-users" or drive out more efficiencies
	Cost Initiatives	Achieved ~$4.7M of cost initiatives in 3Q 2016 – we continue to be on pace to deliver targeted savings by 4Q'17
	Accounts Receivable	DSO increased 3 days from 2Q 2016 to 40 by end of 3Q 2016. Expected to return to normal during 1Q'17
	Home Health	Growth below expectations for quarter - over 50% of census in some stage of HCHB implementation in 3Q'16. Initial 2017 growth projections strong, regulatory headwinds impactful
	Hospice	SS Hospice admissions +16%. 6th consecutive quarter of double digit growth
	Personal Care	Billable hours/quarter: +8%, Clients served: +11%. Integration process best-in-class
	M&A	$100M in capital deployed in last 12 months. Pipeline remains strong, maintaining pricing discipline.
	Reimbursement	Home Health final rule announced. Changes in scoring being evaluated internally. PCR delayed

Ongoing Initiative

- Clinical leadership developing protocols for 2017 rollout. Will use to drive care standardization and deliver resources at site of care

- Continued focus on People through engagement planning and development opportunities
- Productivity and staffing tool has been developed and is being piloted in the field will drive capacity

- Disruption of ~$18,000 per care center will wind down in early 2017 at which time focus will shift to HCHB 2.0 training
- A/R increase related to process changes from HCHB implementation (billing from two systems until AMS2 wind down). HCHB 2.0 training and AMS2 sunset will improve A/R

- Piloting Home Health Sales Reorg initiatives - results are encouraging, with 2% incremental Medicare growth driven by increased staff productivity.
- Targeting 5-6% annual organic growth rate
- Focusing M&A efforts across all business lines, while maintain multiple discipline
- Reimbursement headwinds in Home Health and tailwinds in Hospice in 2017

Clinical Distinction: Improvements in Stars

Quality of Patient Care (QPC)

Metric	Oct 16 Release	Jan 17 Preview	Apr 17 Preview
Quality of Patient Care	3.74	3.91	**4.03**
Entities at 4+ Stars	50%	65%	**75%**

Patient Satisfaction (PS)

Metric	Apr 16 Release	Jul 16 Release	Oct 16 Release
Patient Satisfaction Star	3.90	3.88	3.76
Performance Over Industry	+7%	+6%	+5%





- Amedisys achieves a 4-Star average in the April 2017 HHC release with 75% of providers at 4+ Stars
- Five Amedisys providers rated at 5-Stars in the January 2017 Preview
- Patient Satisfaction (HHCAHPS) results remain stronger than overall industry average

Stars and Growth

4Q14-3Q15 v 4Q15-3Q16 Admits

APR 17 Provider Rating	Provider #'s	Growth
★★½ / ★★★	7	-5%
★★★½	38	-1%
★★★★	75	4%
★★★★½ /★★★★★	53	6%

- At the Overall Star Rating level, general trend is that the total admit growth of 4+ Star agencies was better than growth for those less than 4
- In aggregate, agencies that perform better on Stars metrics tend to perform better on growth metrics

Value Based Purchasing

Performance in VBP States Relative to Industry

	QPC Star Average	PS Star Average
Amedisys VBP State Avg	**3.83**	**3.64**
Large Cohort VBP Comp Avg[1]	3.51	3.50

Internal analysis suggests that we will be a net receiver of funds in 2018 though reimbursement methodology makes +3% achievement challenged

Note: *Top Competitor Avg weighted by CCN count and include LHC, Kindred, AFAM, HLS and BKD*

Becoming Employer of Choice: Improving Return on Human Capital



- Total voluntary turnover continues to decline, closing in on goal of 22% by end of 2016
  - Full-time clinician turnover (who are accountable for 83% of total visits) has dropped to 18%
  - Corporate and two regions have achieved annual goal
- Implementation of HCHB allowing for increase in productivity targets
- Piloting proprietary resource allocation and productivity tool to maximize visiting clinician's capacity to achieve growth targets

*Trailing 12 months

Operational Excellence: Roadmap to EBITDA Improvement

HCHB disruption cost deeper than originally estimated but still contained to 2016



- Incremental disruption driven by: recert rate impact, increased: OT pay, wireless, mileage, and other back office costs
- Revised Disruption: **~$18,000** per care center plus ~$600,000 of incremental corporate expense per quarter
- Minimal to no impact in early 2017

HCHB Disruption	**2016**					**2017 (E)**				
($M)	***Q1**	**Q2**	**Q3**	**Q4 (E)**	**FY 2016**	**Q1**	**Q2**	**Q3**	**Q4**	**FY 2017**
Original	$ (0.3)	$ (0.6)	$ (0.8)	$ (0.8)	$ (2.5)	$ -	$ -	$ -	$ -	$ -
Revised	$ (1.8)	$ (2.4)	$ (2.4)	$ (1.8)	$ (8.4)	$ (0.8)	$ -	$ -	$ -	$ (0.8)
Variance	$ (1.5)	$ (1.8)	$ (1.6)	$ (1.0)	$ (5.9)	$ (0.8)	$ -	$ -	$ -	$ -
Actual	$ (1.8)	$ (2.4)	$ (2.7)							

*1Q'16 updated from original estimate of ($0.4)

Operational Excellence: Roadmap to EBITDA Improvement

All centers officially on HCHB Nov. 1. Disruption costs have been deeper than originally estimated but contained and return to normal 60-90 days post-implementation. 2/28/17 last post-implementation day for final care center cohort. Tracking towards projected $46M annualized savings by YE 2017



NET IMPACT	2016					2017 (E)				
($M)	Q1	Q2	Q3	Q4	FY 2016	Q1	Q2	Q3	Q4	FY 2017
Efficiencies (Plan)	$ -	$ 1.0	$ 3.5	$ 5.5	$ 10.0	$ 8.5	$ 10.3	$ 11.1	$ 11.6	$ 41.4
Revised Disruption	$ (1.8)	$ (2.4)	$ (2.7)	$ (1.8)	$ (8.7)	$ (0.8)	$ -	$ -	$ -	$ (0.8)
Net Impact	$ (1.8)	$ (1.4)	$ 0.8	$ 3.7	$ 1.3	$ 7.7	$ 10.3	$ 11.1	$ 11.6	$ 40.7

*Run rate: $46.4M

Operational Excellence: HCHB Implementation Timeline

During 3Q 2016 ~50% of our patient census were in some phase of HCHB implementation.



Total Care Centers in any phase of implementation:	3Q'15	4Q'15	1Q'16	2Q'16	3Q'16	4Q'16	1Q'17	2Q'17
	15	***74***	***115***	***163***	***174***	***97***	***68***	***0***

What's Going Well

- Clinician adoption to new workflow
- Reporting and clinical excellence classes have been effective in driving quality
- Staffing model savings are being realized
- Field leaders own implementation process

Implementation Disruption and Impact Update

- 6 of 9 regions have experienced recert disruption related to HCHB implementation
- Have seen temporary increases in wireless, OT/Admin, mileage and help desk costs
  - *Incremental increases return to normal with 60-90 days (post HCHB implementation)*

Note: Since rollout started, 1 Hospice and 2 Home Health centers closed

Operational Excellence: Cost Per Visit (CPV)

CPV increase driven by planned raises, health insurance costs, and HCHB disruption



Components	3Q'15	3Q'16	Variance	Detail	Mitigation Plan
Salaries	$60.12	$62.34	$2.22	$1.00 driven by salary increases	Expect normal levels post HCHB.
				$0.50 HCHB disruption due to Admin/OT	Will reduce as rollout is completed
				$0.40 clinician mix	Initiative focused on optimizing clinician mix (RN / LPN, PT / PTA)
Contractors	$2.48	$2.61	$0.13	Trend down since 1Q16 and sequentially; ~$0.40/visit in total	Contractor utilization decreases as clinician capacity increases post HCHB
Benefits	$9.93	$10.94	$1.01	Health insurance driving ~$1.00 of increase	Focused on cost containment and spend optimization
Transportation & Supplies	$6.48	$6.97	$0.49	HCHB-driven duplicative transportation costs	Return to normal levels post HCHB
*Visiting Staff CPV	$79.01	$82.86	$3.85		
Clinical Managers	$8.53	$8.72	$0.19	Fixed cost associated with non-visiting clinicians	Unit cost reduced as volume increases
Total CPV	$87.54	$91.58	$4.04		

Note: Direct comparison with industry competitors CPV calculation

Amedisys

Driving Top Line Growth: Positive Metrics Across Business Segments

We continue to grow across all lines of business



* Includes 3,792 (Q1), 3,958 (Q2) and 3,608 (Q3) completed episodes from Infinity acquisition







* Includes 19,000 (3Q15), 60,000 (4Q15), 62,000 (1Q16), 63,000 (2Q16) and 114,000 (3Q16) hours related to acquired assets

Amedisys

CMS Update: Home Health and Hospice Reimbursement

Home Health Medicare Reimbursement	FY16	FY17 Final
Market basket update	2.3%	2.8%
Productivity adjustment	(0.4%)	(0.3%)
Rebasing	(2.4%)	(2.3%)
Nominal case-mix adjustment	(1.0%)	(0.9%)
Net impact – Industry	(1.5%)	(0.7%)
Case mix reweighting / Other Company Specific Impact	(0.2%)	~(1.3%)
Approximate Impact ($M / %)	($14) / (1.7%)	~($17) / ~(2.0%)

Hospice Medicare Reimbursement	FY16	FY17 Final
Market basket update	2.4%	2.7%
Productivity adjustment	(0.8%)	(0.6%)
Routine LOS Reimbursement Change	(1.6%)	--
Net impact – Industry	0.0%	2.1%
Approximate Impact to Amedisys ($M)	$0	$5

Estimated Annual Pricing Impact – Consolidated ($M)	**($14)**	**~($12)**

Amedisys®

Debt and Liquidity Metrics

Outstanding Debt	As of: 09/30/16
Term Loan	96.2
Outstanding Revolver / Other Notes Payable	0.7
Total Debt Outstanding	**96.9**
Less: Deferred Finance Fees	(2.8)
Total Debt - Balance Sheet	**94.1**
Total Debt Outstanding	96.9
Less: Cash	(8.9)
Net Debt	**88.0**
Leverage Ratio (net) (1)	**0.8x**

Despite deploying over $100M toward acquisitions and share repurchases in the past 15 months, total leverage remains close ~1.0x and stands at 0.8x on a net debt basis

$300M Credit Facility	As of: 09/30/16
Revolver Size	200.0
Oustanding Revolver	0.0
Letters of Credit	26.7
Available Revolver	**173.3**
Plus: Cash	8.9
Total Liquidity (2)	**182.2**

Credit facility and cash provide significant dry powder for accretive acquisitions and/or other capital deployment options

1. *Net debt defined as total debt outstanding ($97M) less cash balance ($9M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($107M).*
2. *Liquidity defined as the sum of cash balance and available revolving line of credit.*

Adjusted EBITDA to Free Cash Flow Reconciliation [1,2]

S in Millions	3Q15	4Q15	1Q16	2Q16	3Q16	LTM 9/30
GAAP Net Income	8.4	12.9	6.2	10.7	11.4	41.2
Taxes	6.5	9.6	4.4	7.2	6.7	27.9
Interest	4.9	1.0	1.1	1.3	1.1	4.5
Depreciation and amortization	4.6	4.2	4.5	5.0	5.2	18.9
Adjustments	1.9	(0.1)	7.8	5.6	1.2	14.5
Adjusted EBITDA	**26.4**	**27.6**	**23.9**	**29.8**	**25.6**	**106.9**
Provision for doubtful accounts	3.6	4.7	3.9	4.2	5.5	18.3
Non-cash compensation, includes 401(k) match expense	4.2	5.7	5.8	5.4	6.4	23.3
Cash taxes	(0.1)	(0.9)	-	(0.8)	-	(1.7)
Cash interest	(2.0)	(0.6)	(0.6)	(0.7)	(0.9)	(2.8)
Other	(2.7)	(3.9)	(10.9)	(14.1)	(1.8)	(30.7)
	29.4	**32.6**	**22.1**	**23.8**	**34.8**	**113.3**
Changes in working capital	1.3	(12.6)	(9.9)	(9.1)	(28.0)	(59.6)
Cash Flow from Operations	**30.7**	**20.0**	**12.2**	**14.7**	**6.8**	**53.7**
Capital Expenditures - Routine	(0.6)	(2.6)	(3.1)	(2.0)	(1.6)	(9.3)
Required debt repayments	0.0	0.0	(1.3)	(1.3)	(1.3)	(3.9)
Free cash flow	**30.1**	**17.4**	**7.8**	**11.4**	**3.9**	**40.5**
Capital Deployment						
Acquisitions	(5.8)	(63.3)	(27.7)	0.0	(3.7)	(94.7)
Share Repurchases	0.0	(4.6)	(12.3)	0.0	0.0	(16.9)
Total	**(5.8)**	**(67.9)**	**(40.0)**	**0.0**	**(3.7)**	**(111.6)**

1. *The financial results for the three-month periods ended September 30, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.*
2. *Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.*

Amedisys®

Income Statement Adjustments (1)

$000s	Income Statement Line Item	3Q15	4Q15	1Q16	2Q16	3Q16
Reduction of cost report reserve	Revenue		(1,059)			
Third Party Audit reserve	Revenue				948	
G&A						
Acquisition costs	G&A, Salary and benefits			502	154	101
Restructuring Activity	G&A, Salary and benefits	230		1,149	1,201	2,044
HCHB implementation	G&A, Salary and benefits				307	56
Restructuring Activity	G&A, Non-cash compensation	(174)			(556)	(493)
Restructuring Activity	G&A, Other			1,061	849	414
HCHB implementation	G&A, Other	2,048	2,383	2,440	2,286	1,937
Acquisition costs	G&A, Other		1,046	1,202	183	366
Legal fees - non-routine	G&A, Other	286	2,824	1,517	459	374
Disaster Relief	G&A, Other					339
Other Items						
Asset impairment	Asset impairment	2,075				
Debt refinance costs	Interest expense	3,212				
Legal settlements	Other, Miscellaneous, net	(1,014)	(5,314)	(541)	(265)	(1,242)
Miscellaneous, other (income) expense, net	Other, Miscellaneous, net	(1,563)		436	70	(2,738)
Total		**5,100**	**(120)**	**7,766**	**5,636**	**1,158**
EPS Impact		**$0.09**	**$0.02**	**$0.14**	**$0.10**	**$0.02**

1. *The financial results for the three-month periods ended September 30, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.*

Amedisys®